Rm. 427, 2206 East Mall
Vancouver, BC V6T 1Z3

Gina Ogilvie, MD MSc FCFP DrPH is Professor at the School of Population and Public Health at the University of British Columbia. She is also the Medical Director of Clinical Prevention Services at the BC Centre for Disease Control. Dr. Ogilvie provides both operational and scientific leadership for Clinical Prevention Services, an integrated public health unit with over 100 staff at the BC Centre for Disease Control which focuses on providing public health leadership and service in STIs, HIV, Hepatitis and Tuberculosis provincially, nationally and globally. Dr. Ogilvie is currently principal investigator on over 12 million dollars in research grants and she has received funding from PHAC, CIHR, Michael Smith Foundation for Health Research and private foundations among others. Her research is focused on both the public health and clinical aspects of reproductive health, sexually transmitted infections, HPV screening and the HPV vaccine, and her findings have been highly influential in setting and directing health policy both in Canada and globally. Among other research projects, she is principal investigator for the ASPIRE program, a global health initiative conducting research and providing women-centred, innovative solutions for cervical cancer prevention and reproductive health in sub-Saharan Africa. She has published over 80 peer reviewed manuscripts and has provided advice and consultation to national and global institutions, including the Canadian Partnership Against Cancer, Public Health Agency of Canada, the World Health Organization and Ministries of Health globally on STI, HIV and HPV vaccine policy and programming. She speaks widely at international and national research and education conferences, and has supervised medical students, residents, and graduate students throughout her career. Dr. Ogilvie received her MD from McMaster University, and completed a specialty in Family Medicine and a fellowship in Population Health and Primary care. She received her Masters of Science at UBC, and her Doctorate in Public Health from the University of North Carolina Gillings School of Global Public Health.

Bachelor of Science (Honours), Queen’s University, Kingston; MD, McMaster University, Hamilton; Fellowship in Population Health and Primary Care, McMaster University, Hamilton; Master of Science, University of British Columbia, Vancouver; Doctorate of Public Health, UNC Gillings School of Global Public Health, Chapel Hill, North Carolina

Recipient, Arthur B. Holzworth Endowed Scholarship, University of North Carolina, Gillings School of Global Public Health, April 2011; Recipient, Award of Merit, Top Innovation – Health Authority (Reduced Dosing Schedules for Gardasil Vaccination for Grade 6 Girls in BC project), 5th Annual Excellence in BC Health Care Awards, June 2011.

(Selected publications)

Ogilvie GS, Taylor DL, Moniruzzaman A, Knowles L, Jones H, Kim P, Rekart ML. A population-based study of infectious syphilis rediagnosis in BC, 1995-2005. Clinical Infectious Diseases 2009;481:554-8.

Ogilvie GS, Anderson M, Marra F, McNeil S, Pielak K, Dawar M, McIvor M, Ehlen T, Dobson S, Money D, Patrick DM, Naus M. A Population-Based Evaluation of a Publicly Funded, School-based HPV Vaccine Program in British Columbia, Canada: Parental Factors Associated with HPV Vaccine Receipt. Public Library of Science Medicine. 2010 May 4;7(5):e1000270.

Ogilvie GS, Krajden M, van Niekerk DJ, Martin RE, Ehlen TG, Ceballos K, Smith LW, Kan L, Cook DA, Peacock S, Stuart GC, Franco EL, Coldman AJ. Primary cervical cancer screening with HPV testing compared to liquid based cytology: Results of round 1 of a randomized controlled trial – the HPV FOCAL Study. British Journal of Cancer 2012 Dec 4;107(12):1917-24

Simon RM Dobson, Shelly McNeil, Marc Dionne, Meena Dawar, Gina Ogilvie, Mel Krajden, Chantal Sauvageau David W Scheifele, Tobias R Kollmann, Scott A Halperin, Joanne M Langley, Julie A Bettinger, Joel Singer, Deborah Money, Dianne Miller, Monika Naus, Fawziah Marra, Eric Young. A randomized controlled trial to assess immunogenicity of a two-dose quadrivalent human papillomavirus vaccine schedule in Canadian younger adolescents: Results to Month 36. Journal of the American Medical Association 2013; 309(17):1793-1802

Ogilvie GS, Mitchell S, Sekikubo M, Biryabarema C, Byamugisha J, Jeronimo J, Krajden M, van Niekerk D, Miller D, Christilaw J, Steinberg M, Money DM. Results of a community-based cervical cancer screening pilot project using human papillomavirus self-sampling in Kampala, Uganda. International Journal of Gynaecology and Obstetrics 2013; Aug;122(2):118-123

Ogilvie GS, Smith L, van Niekerk DJ, Khurshed F, Krajden M, Saraiya M, Goel V, Rimer B, Greene S, Hobbs S, Coldman AJ, Franco EL. Women’s intentions to receive cervical cancer screening with primary human papillomavirus testing. International Journal of cancer 2013;133:2934-2943

Human papillomavirus; sexually transmitted infections; women’s health; global health; cerivcal cancer; screening; HPV vaccine